4117.TWO General Biologicals Corporation

Healthcare Drug Manufacturers - Specialty & Generic Taiwan OTC Exchange
8.70 TWD
Close of Nov 6, 2026
3.50 17.30
Market cap
TWD 616M
P/E
1.0x
P/B
0.52x
ROE
53.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4117.TWO undervalued?

Graham number

The Graham number of General Biologicals Corporation cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

General Biologicals Corporation fundamental analysis

No fundamental analysis for General Biologicals Corporation yet.

General Biologicals Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About General Biologicals Corporation

General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. The company offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point-of-care testing services. It also provides Oncology & Liquid Biopsy; blood safety and screening services for hepatitis and HIV; contract development and manufacturing; IVD reagents and biomaterials. In addition, the company offers…

Full company profile